HT-ALZ

HT-ALZ is a proprietary, orally bioavailable formulation of an FDA-approved neurokinin 1 (NK-1) receptor antagonist developed by Hoth Therapeutics for the treatment of Alzheimer's disease. It is designed to cross the blood-brain barrier and selectively target astrocyte-driven neuroinflammation, a key contributor to cognitive decline in Alzheimer's. Preclinical studies in APP/PS1 mouse models have demonstrated that both acute and chronic administration of HT-ALZ leads to significant improvements in memory, reduction of anxiety-like behavior, enhanced sensorimotor gating, and no impairment of motor function. Mechanistically, HT-ALZ reduces GFAP-positive reactive astrocytes and rapidly lowers brain interstitial fluid amyloid-beta (Aβ) levels (~15% within 20 hours), indicating dual action on both pathological processes (amyloid pathology and inflammation) and symptoms. The drug leverages established safety data from its parent NK-1 antagonist compound but represents a novel approach by focusing on modulation of neuroinflammation rather than solely targeting amyloid plaques[2][4][5][8].

Brand names

HT-ALZ

Other names

HT-ALZ